Zobrazeno 1 - 10
of 71
pro vyhledávání: '"seribantumab"'
Autor:
Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. Howe
Externí odkaz:
https://doaj.org/article/3595f6bd2f1948ae89b5ca12ff495d0f
Autor:
Charles Dahlsson Leitao, Sara S. Rinne, Mohamed Altai, Olga Vorontsova, Finn Dunås, Per Jonasson, Vladimir Tolmachev, John Löfblom, Stefan Ståhl, Anna Orlova
Publikováno v:
Pharmaceutics, Vol 12, Iss 6, p 551 (2020)
Human epidermal growth factor receptor 3 (HER3) has been increasingly scrutinized as a potential drug target since the elucidation of its role in mediating tumor growth and acquired therapy resistance. Affibody molecules are so-called scaffold protei
Externí odkaz:
https://doaj.org/article/148da783456d45d6a6e536a64f936017
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stephen V. Liu
Publikováno v:
Lung Cancer. 158:25-28
NRG1 fusions are rare oncogenic drivers that exist at low frequencies across multiple tumor types. They are uncommon in lung cancer with an estimated incidence of 0.2 %. NRG1 fusions have a unique biology and are challenging to detect, due to large i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a8918944f533db264c1f39902f112ec
https://doi.org/10.1016/j.lungcan.2021.05.011
https://doi.org/10.1016/j.lungcan.2021.05.011
Autor:
Elisa de Stanchina, Allan J.W. Lui, Marissa Mattar, Whitney J. Sisso, Lukas Delasos, Exequiel M. Sisso, Renate I. Kurth, Zebing Liu, Marc Ladanyi, Eric Gladstone, Shawn M. Leland, Igor Odintsov, Romel Somwar, Morana Vojnic, Inna Khodos
Publikováno v:
Clinical Cancer Research. 27:3154-3166
Purpose: Oncogenic fusions involving the neuregulin 1 (NRG1) gene are found in approximately 0.2% of cancers of diverse histologies. The resulting chimeric NRG1 proteins bind predominantly to HER3, leading to HER3-HER2 dimerization and activation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abe29eefb9056e32a3314faa1a991be3
https://doi.org/10.1158/1078-0432.ccr-20-3605
https://doi.org/10.1158/1078-0432.ccr-20-3605
Autor:
Rinne, Sara S., Dahlsson Leitao, Charles, Abouzayed, Ayman, Vorobyeva, Anzhelika, Tolmachev, Vladimir, Ståhl, Stefan, Löfblom, John, Orlova, Anna
Publikováno v:
Cancers, Vol 13, Iss 4791, p 4791 (2021)
Cancers
Cancers
Simple Summary HER3 is a known driver for oncogenesis and therapy resistance in solid cancers. PET imaging could be a useful tool to non-invasively detect and monitor HER3 expression and aid in the selection of patients for HER3-targeted therapy. PET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::02c55e1d28aa4b751418505eb3b82264
https://www.mdpi.com/2072-6694/13/19/4791
https://www.mdpi.com/2072-6694/13/19/4791
Autor:
Jordan M. Winter, Joseph Willis, Fan Fan, Zhenghe Wang, Rajat Bhattacharya, Michel’le Wright, Lee M. Ellis, Sanford D. Markowitz, Ali Vaziri-Gohar, Rui Wang, Moeez Ghani Rathore
We previously showed that human epidermal growth factor receptor 3 (HER3, also known as ERBB3) is a key mediator in liver endothelial cell (EC) promoting colorectal cancer (CRC) growth and chemoresistance, and suggested HER3-targeted therapy as a str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::652a19f48fd06e1c95b9d676519a9304
https://doi.org/10.21203/rs.3.rs-745208/v1
https://doi.org/10.21203/rs.3.rs-745208/v1
Publikováno v:
Investigational New Drugs
BACKGROUND: Overactivation of human epidermal growth factor receptor 3 (HER3) triggers multiple intracellular pathways resulting in tumor cell survival. This Phase 1 study assessed the safety, efficacy, and pharmacokinetics (PK) of seribantumab, a fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0579914e5565bffcd2f90017da6e3ad9
https://doi.org/10.21203/rs.3.rs-484551/v1
https://doi.org/10.21203/rs.3.rs-484551/v1
Autor:
Moeez Rathore, Michel’le Wright, Rajat Bhattacharya, Fan Fan, Ali Vaziri-Gohar, Jordan Winter, Zhenghe Wang, Sanford D Markowitz, Joseph Willis, Lee M. Ellis, Rui Wang
We previously showed that liver endothelial cells (ECs) secreted soluble factors in a paracrine fashion and activated human epidermal growth factor receptor 3 (HER3, also known as ERBB3) for promoting colorectal cancer (CRC) growth and chemoresistanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d841c9587fc986b9ce6f8e21b3f5d268
https://doi.org/10.1101/2021.04.27.441690
https://doi.org/10.1101/2021.04.27.441690
Autor:
Gigliola Reato, Carmine Dell'Aglio, Serena Pellegatta, Laura Casorzo, Monica Patanè, Geoffrey Kuesters, Bianca Pollo, G. Finocchiaro, Raffaella Albano, Francesca Orzan, Elena Casanova, Francesca De Bacco, Antonio D'Ambrosio, Viola Bigatto, Carla Boccaccio, Paolo M. Comoglio, Ludovic Barault, Jessica Erriquez
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109455-(2021)
Summary In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71490ed6a4f68d953fba7cb26eb5eb77
http://hdl.handle.net/2318/1795377
http://hdl.handle.net/2318/1795377